Shares of The Ensign Group surged 6.3% to $180.25 in pre-market trading October 28, as investors cheered a third-quarter earnings beat and a raised full-year outlook — even as the skilled-nursing operator fights a securities fraud class action and allegations of patient neglect from short sellers.
• Profits Grew Faster Than Revenue, and That's What Wall Street Noticed
GAAP diluted earnings per share hit $1.76, up 23.9% year over year, while adjusted EPS of $2.03 rose 23.8%. The adjusted figure topped the $1.97 consensus estimate by roughly 3%. Revenue of $1.48 billion grew 14.5% but missed consensus of $1.60 billion by 7.1%. Investors largely shrugged off the revenue shortfall because profitability is accelerating: adjusted net income jumped 24.9% to $120.5 million , and adjusted EBITDA — a measure of operating cash earnings — hit $190.7 million, beating estimates by 2.4%. The message: Ensign is squeezing more profit out of each dollar of revenue.
• A Third Consecutive Guidance Raise Signals Management Confidence
Management lifted 2026 adjusted EPS guidance to $7.94–$8.02, up from the prior $7.75–$7.85 range. That midpoint of $7.98 sits well above analyst consensus. Ensign has now raised guidance every quarter this year — from $7.48–$7.62 after Q1
to $7.75–$7.85 after Q2 — creating a pattern of under-promising and over-delivering that builds credibility on the Street.
• Occupancy and Higher-Acuity Patients Are Driving the Upside
Same-facility occupancy reached 84.1%, up 1.6 percentage points year over year, while transitioning facilities hit 86.1%, up 3.9 points. Critically, skilled-mix revenue — care for sicker patients who generate higher reimbursement rates — rose 10.7% at same facilities. Fuller beds plus higher-paying patients explains why margins are expanding even as revenue missed.
• Legal Headwinds Are Real and Not Priced Into the Celebration
In June, Hunterbrook Media published an investigation alleging Ensign cut registered-nurse hours, used self-reported data to inflate quality ratings, and profited by providing less care than patients required.
A securities fraud class action now covers investors who bought shares between February 2022 and June 2026, with a lead-plaintiff deadline of December 7.
Ensign also faces a DOJ Civil Investigative Demand regarding billing practices. Strong earnings may buy time, but these probes target the very business model generating today's profits — a tension investors should not ignore.